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Fig. 1. Mean NRG1/G3PDH mRNA ratios in healthy controls, high-risk individuals who
later developed psychosis (converters), and in those who did not develop psychosis
(non-converters). Error bars indicate standard deviations.Decreased peripheral expression of neuregulin 1 in high-risk
individuals who later converted to psychosis
Dear Editors,
Efforts to identify individuals with high psychosis risk have
focused on biological markers that show a marked association with
later conversion to full-blown psychosis. Hall et al. (2006) found
that a variant in the human neuregulin 1 (NRG1) promoter region
is associated with increased development of psychotic symptoms
in high-risk individuals. These results were replicated in a Hungarian
sample (Kéri et al., 2009). NRG1 plays an important role in neurode-
velopment and synaptic plasticity by the regulation of glutamatergic
and gamma-amynobutiric acidergic (GABAergic) neurons, and its
risk variants are related to altered gene expression in postmortem
brain tissue (Law et al., 2006). Previous studies demonstrated
decreased peripheral NRG1expression in schizophrenia (Chagnon
et al., 2008; Zhang et al., 2008), but it is not clear whether these
changes can reliably predict psychosis conversion in high-risk
individuals.
In order to elucidate this issue, we enrolled 97 help-seeking indi-
viduals who visited the outpatient units of the University of Szeged,
Bács-Kiskun Country Hospital, and Semmelweis University, Hungary.
The control group included 50 healthy volunteers with a negative
family history for psychotic disorders. Ultra-high-risk status was
evaluated using the Comprehensive Assessment of At-Risk Mental
States (CAARMS) (McGorry et al., 2003; for a study description, see
Kéri et al., 2009).
For the measurement of NRG1 isoforms, we adopted the proto-
col of Zhang et al. (2008). Blood was drawn from the cubital vein
into a sterile plastic tube. Total RNA was extracted and reverse
transcribed into ﬁrst-strand cDNA. Two isoforms of NRG1 were
measured using semi-quantitative reverse transcriptase polymerase
chain reaction (RT-PCR) (glial growth factor-2 [GGF2, type II] and
heregulin beta 3 [HRG-beta3, type I]; upstream primer: 5′-
CTTTCTTGTTGCTGCATCTCC-3′; downstream primer: 5′-CACCCTTTT-
CAGGATGTGGT-3′). Glyceraldehyde-3-Phosphate Dehydrogenase
(G3PDH) was the internal control because its level is unchanged
in schizophrenia (upstream primer: 5′-ACCACAGTCCATGCCATCAC-
3′; downstream primer: 5′-TCCACCACCCTGTTGCTGTA-3′). We
used cDNA for ampliﬁcation with upstream and downstream
primers of NRG1 and G3PDH, Taq DNA polymerase, dNTP, and
PCR buffer. The protocol of the DNA thermal cycler included the
following steps: initial denaturation at 95 °C for 5 min, cycles at
94 °C for 45 s, annealing at 65 °C (G3PDH at 62 °C) for 30 s, and ex-
tension at 72 °C for 90 s (35 cycles for NRG1 and 30 for G3PDH).
Following the electrophoresis of the PCR products (2.0% agarose
gel containing ethidium bromide), the optical density of NRG1
(type I and III combined) and G3PDH mRNA was determined. The
ratio of the NRG1 and G3PDH mRNA optical density was the
dependent measure (Zhang et al., 2008).0920-9964/$ – see front matter © 2011 Elsevier B.V. All rights reserved.
doi:10.1016/j.schres.2011.12.012Of the 97 high-risk individuals enrolled in the study, 31 partici-
pants (32%) developed psychotic disorders (schizophrenia, schizo-
phreniform disorder, psychotic mood disorder) by the end of the
12-month follow-up period (for demographic details, we refer to
Kéri et al., 2009). None of the participants received psychotropic
medications before the ﬁrst psychotic episode. The ANOVA conducted
on the NRG1/G3PDH ratios revealed a signiﬁcant main effect of group
(F(1,144)=16.58, pb0.001). Scheffé's tests indicated that converters
who developed psychosis had lower NRG1/G3PDH ratios compared
with healthy controls (pb0.001) and with non-converter high-risk
individuals who did not develop psychosis (pb0.001). Non-
converters did not differ from controls (p=0.19) (Fig. 1). Age, educa-
tion, IQ, Global Assessment of Functioning (GAF) scores, and CAARMS
values did not correlate with NRG1 mRNA expression (rb0.1, p>0.5).
There was no signiﬁcant difference between male and female par-
ticipants in either group (p>0.1). When age and gender were includ-
ed in the ANOVA as co-variants, the results remained the same.
These preliminary results suggest that peripheral NRG1 mRNA ex-
pression may be a biological marker of psychosis conversion in high-
risk individuals. Limitations of this study include a small sample size,
overlap among groups circumventing a reliable discriminant analysis,
semi-quantitative nature of RT-PCR, and the combined measurement
of two NRG1 isoforms. It is also possible that peripheral leukocyte
mRNA levels do not accurately reﬂect those in the brain, although
consistent alterations in neuronal and peripheral NRG1 expression
have been documented in schizophrenia (Hashimoto et al., 2004;
Petryshen et al., 2005). Therefore, the results of the present study
must be replicated in an independent and larger sample.Contributors
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